These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27012985)

  • 1. Nivolumab-induced thyroid dysfunction.
    Tanaka R; Fujisawa Y; Maruyama H; Nakamura Y; Yoshino K; Ohtsuka M; Fujimoto M
    Jpn J Clin Oncol; 2016 Jun; 46(6):575-9. PubMed ID: 27012985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
    Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
    BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
    Yuki A; Takenouchi T; Takatsuka S; Ishiguro T
    Melanoma Res; 2017 Dec; 27(6):635-637. PubMed ID: 28872489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
    Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
    Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
    Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
    Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer.
    Badovinac S; Korsic M; Zarkovic K; Mursic D; Roglic M; Jakopovic M; Samarzija M
    Immunotherapy; 2018 Mar; 10(6):427-431. PubMed ID: 29562858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
    Okiyama N; Tanaka R
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.
    Maekura T; Naito M; Tahara M; Ikegami N; Kimura Y; Sonobe S; Kobayashi T; Tsuji T; Minomo S; Tamiya A; Atagi S
    In Vivo; 2017; 31(5):1035-1039. PubMed ID: 28882978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab induced myxedema crisis.
    Khan U; Rizvi H; Sano D; Chiu J; Hadid T
    J Immunother Cancer; 2017; 5():13. PubMed ID: 28239466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].
    Qi L; Mo HN; Chen XL; Wang X; Wu DW; Lan B; Li Q; Wang XY; Xu JP; Yang Q; Xu BH; Huang J
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):772-775. PubMed ID: 30392342
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
    Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
    Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nivolumab-induced hypothyroidism: A case report].
    Lin C; Guo Z; Mo Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Feb; 44(2):222-224. PubMed ID: 30837393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.
    Zeng MF; Chen LL; Ye HY; Gong W; Zhou LN; Li YM; Zhao XL
    Medicine (Baltimore); 2017 Nov; 96(44):e8426. PubMed ID: 29095280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
    Zhang X; Wu Y; Lv J; Li X; Ma L; Nong J; Zhang H; Qin N; Zhang Q; Shi G; Yang X; Wang J; Zhang S
    Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.